Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17256592 | MOT CELLS AS A THERAPEUTIC SCREENING TOOL FOR REGULATORY T-CELL ACTIVITY | December 2020 | March 2022 | Allow | 15 | 1 | 1 | Yes | No |
| 17133702 | INDUCIBLE REGULATORY T-CELL GENERATION FOR HEMATOPOIETIC TRANSPLANTS | December 2020 | May 2025 | Abandon | 53 | 3 | 1 | No | No |
| 17119832 | Therapeutic Methods Involving Modulating Inflammasome Activation of Myeloid-Derived Suppressor Cells | December 2020 | October 2024 | Allow | 46 | 3 | 2 | No | No |
| 17116627 | Compositions and Methods for Selectively Modulating Tregs | December 2020 | December 2023 | Abandon | 36 | 1 | 1 | No | No |
| 17114398 | COSTIMULATION OF CHIMERIC ANTIGEN RECEPTORS BY MYD88 AND CD40 POLYPEPTIDES | December 2020 | January 2024 | Abandon | 37 | 1 | 1 | No | No |
| 17059727 | PERSONALIZED TREATMENT OF PANCREATIC CANCER | November 2020 | May 2025 | Allow | 54 | 4 | 1 | No | No |
| 17097682 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS | November 2020 | May 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17091526 | MONOCLONAL ANTIBODIES TARGETING KILLER IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) FAMILY SIGNALING | November 2020 | March 2023 | Allow | 28 | 0 | 0 | No | No |
| 17052133 | BIOMARKERS FOR A COMBINATION THERAPY COMPRISING LENVATINIB AND A PD-1 ANTAGONIST | October 2020 | March 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17063056 | HIGH AFFINITY NY-ESO T CELL RECEPTORS | October 2020 | October 2023 | Abandon | 36 | 1 | 0 | No | No |
| 17062877 | Methods and Materials for the Generation of Regulatory T Cells | October 2020 | July 2024 | Allow | 45 | 2 | 1 | Yes | No |
| 17062234 | METHOD OF ENHANCING PERSISTENCE OF ADOPTIVELY INFUSED T CELLS | October 2020 | October 2023 | Allow | 36 | 1 | 1 | No | No |
| 17031187 | METHODS FOR ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | September 2020 | May 2022 | Abandon | 20 | 2 | 0 | Yes | No |
| 17029814 | TARGETING ANEURYSM DISEASE BY MODULATING PHAGOCYTOSIS PATHWAYS | September 2020 | May 2024 | Allow | 44 | 2 | 0 | No | No |
| 17021158 | IN VITRO IMMUNE SYNAPSE SYSTEM AND METHOD OF IN VITRO EVALUATING IMMUNE RESPONSE USING THE SAME | September 2020 | October 2023 | Allow | 37 | 1 | 1 | Yes | No |
| 17011924 | USE OF GFAP FOR IDENTIFICATION OF INTRACEREBRAL HEMORRHAGE | September 2020 | April 2024 | Abandon | 44 | 1 | 0 | No | No |
| 16997797 | HYBRIDOMA CLONES, MONOCLONAL ANTIBODIES TO VSIG-4, AND METHODS OF MAKING AND USING | August 2020 | October 2023 | Allow | 38 | 2 | 1 | No | No |
| 16991528 | DENDRITIC CELL IMMUNORECEPTOR AGONIST | August 2020 | May 2024 | Abandon | 45 | 2 | 1 | No | No |
| 16983491 | ARTICLES AND METHODS DIRECTED TO PERSONALIZED THERAPY OF CANCER | August 2020 | August 2021 | Allow | 12 | 1 | 1 | Yes | No |
| 16983300 | GENERATION OF DENDRITIC CELLS FROM MONOCYTIC DENDRITIC PRECURSOR CELLS WITH GM-CSF IN THE ABSENCE OF ADDITIONAL CYTOKINES | August 2020 | July 2023 | Allow | 35 | 1 | 0 | No | No |
| 16942058 | COMPOSITIONS AND METHODS FOR PRODUCING DENDRITIC CELLS | July 2020 | June 2023 | Abandon | 34 | 0 | 1 | No | No |
| 16964695 | PEPTIDE EXCHANGE PROTEIN | July 2020 | April 2025 | Allow | 57 | 3 | 1 | Yes | No |
| 16964863 | DENDRITIC CELL VACCINATION IN PARALLEL TO CHEMOTHERAPY | July 2020 | April 2025 | Abandon | 57 | 2 | 1 | No | No |
| 16928884 | Th1 vaccination priming for active immunotherapy | July 2020 | July 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 16907335 | Treatment of SARS-CoV-2 with Dendritic Cells for Innate and/or Adaptive Immunity | June 2020 | December 2022 | Abandon | 30 | 0 | 1 | No | No |
| 16904510 | ANTI-PVRIG ANTIBODIES AND METHODS OF USE | June 2020 | May 2023 | Allow | 35 | 1 | 0 | No | No |
| 16899142 | METHODS FOR OBTAINING REGULATORY T CELLS AND USES THEREOF | June 2020 | July 2024 | Allow | 49 | 4 | 2 | Yes | No |
| 16769634 | COMPOSITIONS AND METHODS FOR IMPROVING PERSISTENCE OF CELLS FOR ADOPTIVE TRANSFER | June 2020 | August 2024 | Allow | 50 | 2 | 1 | Yes | No |
| 16768930 | METHODS OF ENRICHING CELL POPULATIONS FOR CANCER-SPECIFIC T CELLS USING IN VITRO STIMULATION OF MEMORY T CELLS | June 2020 | October 2024 | Allow | 52 | 3 | 1 | No | No |
| 16473394 | METHOD FOR PREPARING ANTIGEN-SPECIFIC REGULATORY T CELLS | June 2020 | August 2023 | Abandon | 49 | 1 | 1 | No | No |
| 16880835 | ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF FOR INHIBITING T REGULATORY CELLS ACTIVITY | May 2020 | February 2023 | Allow | 33 | 1 | 0 | No | No |
| 16879923 | T-REG Cell Expansion | May 2020 | September 2023 | Allow | 39 | 2 | 1 | No | No |
| 16763866 | GENETICALLY ENGINEERED GAMMA DELTA T CELL | May 2020 | October 2023 | Abandon | 41 | 1 | 1 | No | No |
| 16763020 | REGULATORY T CELLS GENETICALLY MODIFIED FOR THE LYMPHOTOXIN ALPHA GENE AND USES THEREOF | May 2020 | December 2022 | Allow | 31 | 1 | 1 | Yes | No |
| 16760893 | NK-92 Cells to Stimulate Anti-Cancer Vaccine | April 2020 | March 2025 | Abandon | 59 | 4 | 1 | Yes | No |
| 16758348 | PLZF+ REGULATORY CD8 T CELLS FOR CONTROL OF INFLAMMATION | April 2020 | January 2025 | Abandon | 57 | 5 | 1 | No | No |
| 16849591 | METHODS AND COMPOSITIONS FOR MODULATING THE IMMUNE SYSTEM | April 2020 | May 2024 | Abandon | 49 | 7 | 1 | Yes | No |
| 16841943 | T-CELL EPITOPE IDENTIFICATION | April 2020 | August 2023 | Abandon | 40 | 2 | 1 | No | No |
| 16753522 | REGULATORY T CELL EPITOPES | April 2020 | April 2022 | Allow | 25 | 0 | 0 | No | No |
| 16647713 | Allogeneic Dendritic Cells For Use In Cancer Treatment | March 2020 | December 2022 | Abandon | 33 | 1 | 1 | No | No |
| 16643982 | DENDRITIC CELL POTENCY ASSAY | March 2020 | May 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16643550 | METHOD AND PREPARATION FOR SORTING OUT T EFFECTOR CELLS USING ANTI-CD127 ANTIBODIES FOR APPLICATIONS IN CELL THERAPY | February 2020 | November 2024 | Allow | 57 | 3 | 1 | Yes | No |
| 16804288 | IMMUNOGENIC PEPTIDES AND THEIR USE IN TRANSPLANTATION | February 2020 | March 2023 | Allow | 37 | 1 | 1 | No | No |
| 16792396 | BTLA AGONIST ANTIBODIES AND USES THEREOF | February 2020 | March 2022 | Allow | 25 | 0 | 0 | No | No |
| 16636215 | MATERIALS AND METHODS FOR INDUCING REGULATORY T CELLS | February 2020 | August 2023 | Allow | 43 | 3 | 1 | No | No |
| 16776371 | LIGHT INHIBITORS FOR ASTHMA, LUNG AND AIRWAY INFLAMMATION, RESPIRATORY, INTERSTITIAL, PULMONARY AND FIBROTIC DISEASE TREATMENT | January 2020 | December 2022 | Abandon | 35 | 1 | 1 | No | No |
| 16748695 | ANTI-PVRIG ANTIBODIES AND METHODS OF USE | January 2020 | November 2022 | Allow | 34 | 2 | 0 | No | No |
| 16742124 | Combination Therapy of Acellular Pro-Tolerogenic and Pro-Inflammatory Preparations for Modulating the Immune System | January 2020 | October 2022 | Abandon | 33 | 0 | 1 | No | No |
| 16631099 | MATURATION OF DENDRITIC CELLS | January 2020 | May 2024 | Allow | 52 | 5 | 1 | Yes | No |
| 16630098 | METHODS FOR INCREASING EXPANSION AND IMMUNOSUPPRESSIVE CAPACITY OF A POPULATION OF CD8+CD45RCLOW/- TREGS | January 2020 | July 2022 | Abandon | 30 | 0 | 1 | No | No |
| 16737672 | MEDICAL TREATMENT METHOD WITH ADMINISTRATION OF DENDRITIC CELLS | January 2020 | October 2022 | Abandon | 33 | 1 | 1 | No | No |
| 16731525 | HOMEOBOX TRANSCRIPTION FACTOR VENTX REGULATES DIFFERENTIATION AND MATURATION OF HUMAN DENDRITIC CELLS | December 2019 | March 2024 | Abandon | 50 | 2 | 1 | No | Yes |
| 16726367 | AGONIST FUSION PROTEIN FOR CD40 AND OX40 AND USES THEREOF | December 2019 | November 2023 | Abandon | 47 | 2 | 1 | No | No |
| 16721356 | MODULATION OF T CELLS WITH BISPECIFIC ANTIBODIES AND FC FUSIONS | December 2019 | July 2022 | Abandon | 31 | 0 | 1 | No | No |
| 16719625 | GAMMADELTA T CELL EXPANSION PROCEDURE | December 2019 | August 2022 | Abandon | 32 | 1 | 0 | No | No |
| 16624009 | TREATMENT OF LIVER FAILURE WITH ACTIVATED T REGULATORY CELLS | December 2019 | September 2022 | Abandon | 33 | 1 | 1 | No | No |
| 16624254 | METHODS FOR PRODUCING REGULATORY IMMUNE CELLS AND USES THEREOF | December 2019 | July 2024 | Abandon | 55 | 3 | 1 | No | No |
| 16624097 | T-CELL EXPANSION METHOD AND USES | December 2019 | February 2025 | Abandon | 60 | 4 | 1 | No | Yes |
| 16719650 | GAMMADELTA T CELL EXPANSION PROCEDURE | December 2019 | August 2022 | Allow | 32 | 2 | 0 | No | No |
| 16470353 | METHOD FOR INDUCING REGULATORY T CELL | December 2019 | April 2022 | Abandon | 34 | 0 | 1 | No | No |
| 16615529 | METHODS FOR GENERATING POLYCLONAL REGULATORY T CELLS | November 2019 | October 2022 | Abandon | 35 | 2 | 1 | No | No |
| 16680659 | TREATMENT METHOD FOR KIDNEY TRANSPLANT REJECTION | November 2019 | June 2022 | Abandon | 31 | 1 | 0 | No | No |
| 16612441 | INTERFERON PRIMED PLASMACYTOID DENDRITIC CELLS | November 2019 | September 2024 | Abandon | 58 | 4 | 1 | No | No |
| 16612481 | Dendritic Cells as a Novel Delivery System for Immunotherapy | November 2019 | July 2023 | Abandon | 44 | 3 | 1 | No | No |
| 16675398 | T CELL BALANCE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | November 2019 | June 2024 | Abandon | 56 | 3 | 2 | No | No |
| 16610461 | METHODS FOR THE STIMULATION OF DENDRITIC CELL (DC) PRECURSOR POPULATION "PRE-DC" AND THEIR USES THEREOF | November 2019 | December 2024 | Abandon | 60 | 6 | 1 | Yes | No |
| 16661038 | THERAPEUTIC VACCINE FOR TREATMENT OF DIABETES TYPE 1 IN CHILDREN, APPLICATION OF THE CELL SORTER AND THE METHOD OF MULTIPLYING TREG CELLS TO PRODUCE THERAPEUTIC VACCINE FOR TREATMENT OF DIABETES TYPE 1 | October 2019 | June 2022 | Abandon | 31 | 1 | 0 | No | No |
| 16601825 | PDL1-Binding Proteins | October 2019 | October 2022 | Allow | 36 | 1 | 1 | No | No |
| 16603454 | CELLULAR POPULATIONS AND USES THEREOF | October 2019 | January 2023 | Allow | 39 | 0 | 1 | Yes | No |
| 16603155 | Methods of Isolating Naive Regulatory T Cells | October 2019 | October 2022 | Abandon | 36 | 1 | 1 | No | No |
| 16500827 | ANALYTICAL METHODS AND ARRAYS FOR USE IN THE SAME | October 2019 | February 2022 | Abandon | 28 | 2 | 2 | No | No |
| 16499599 | A METHOD FOR DETECTING CD4+CD25+GLYCOPROTEIN A33(GPA33)HIGH AND/OR CD4+CD127-GPA33HIGH T CELLS | September 2019 | August 2024 | Allow | 59 | 4 | 1 | Yes | No |
| 16490568 | METHODS OF CULTURING T CELLS AND USES OF SAME | September 2019 | November 2023 | Allow | 50 | 3 | 1 | No | No |
| 16488702 | SHORT-TERM ACTIVATED DC1S AND METHODS FOR THEIR PRODUCTION AND USE | August 2019 | March 2024 | Allow | 55 | 5 | 1 | Yes | No |
| 16486453 | Methods to Enhance Tumor Immunogenicity and Compositions for Autologous Cancer Immunotherapeutic Products Using Modified Tumor Cells and Modified Dendritic Cells | August 2019 | April 2022 | Abandon | 32 | 1 | 1 | No | No |
| 16537280 | NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES | August 2019 | March 2022 | Allow | 32 | 1 | 0 | No | No |
| 16484238 | ANTI-ILT3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | August 2019 | October 2021 | Allow | 27 | 1 | 1 | No | No |
| 16484071 | IMMUNOLOGICAL BIOMARKER FOR PREDICTING CLINICAL EFFECT OF CANCER | August 2019 | November 2021 | Allow | 28 | 1 | 1 | Yes | No |
| 16530104 | REGULATORY T CELL EPITOPES, COMPOSITIONS AND USES THEREOF | August 2019 | April 2022 | Abandon | 33 | 1 | 1 | No | No |
| 16482094 | Plasmacytoid Dendritic Cells Having Immune Tolerance, and Method for Producing Same | July 2019 | December 2021 | Abandon | 28 | 0 | 1 | No | No |
| 16482096 | Pharmaceutical Composition for Preventing or Treating Autoimmune Disease, and Method for Producing Same | July 2019 | November 2022 | Abandon | 40 | 1 | 1 | No | No |
| 16479740 | MODIFIED T CELLS AND USES THEREOF | July 2019 | November 2022 | Abandon | 40 | 1 | 1 | No | No |
| 16478995 | COMPOSITIONS AND METHODS FOR TRANSPLANT RECIPIENT CONDITIONING | July 2019 | May 2023 | Abandon | 46 | 2 | 1 | No | No |
| 16502498 | Molecular Complex for Targeting Antigens Towards Cells Comprising Antigens and Uses Thereof for Vaccination | July 2019 | February 2025 | Allow | 60 | 4 | 1 | Yes | Yes |
| 16502433 | STIMULATION OF THERAPEUTIC ANGIOGENESIS BY T REGULATORY CELLS | July 2019 | November 2022 | Abandon | 41 | 1 | 1 | No | No |
| 16475924 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) WITH TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (TNFRSF) AGONISTS AND THERAPEUTIC COMBINATIONS OF TILS AND TNFRSF AGONISTS | July 2019 | August 2023 | Abandon | 49 | 2 | 1 | No | No |
| 16475578 | PERSONALIZED VACCINES | July 2019 | October 2022 | Abandon | 39 | 1 | 1 | No | No |
| 16470098 | IL-13 SUPERKINE: IMMUNE CELL TARGETING CONSTRUCTS AND METHODS OF USE THEREOF | June 2019 | December 2023 | Abandon | 54 | 2 | 1 | No | No |
| 16465773 | COMPOSITIONS AND METHODS FOR IN VITRO CULTIVATION AND/OR EXPANSION OF REGULATORY T CELLS | May 2019 | March 2022 | Allow | 33 | 2 | 1 | Yes | No |
| 16421763 | STEROID ADMINISTRATION AND IMMUNOTHERAPY | May 2019 | November 2021 | Abandon | 30 | 2 | 1 | No | No |
| 16462733 | FRACTAL COMBINATION THERAPY | May 2019 | September 2022 | Allow | 40 | 6 | 1 | Yes | No |
| 16407699 | DISTINGUISHING ANTAGONISTIC AND AGONISTIC ANTI B7-H1 ANTIBODIES | May 2019 | May 2021 | Abandon | 25 | 0 | 1 | No | No |
| 16404091 | THERAPY AND METHODS OF INTRODUCING IMMATURE DENDRITIC CELLS AND/OR CYTOXIC T LYMPHOCYTE AND ANTI PD-1 / PD-L1 ANTIBODY FOR TREATMENT OF TUMORS | May 2019 | May 2023 | Abandon | 49 | 3 | 1 | No | No |
| 16398472 | HUMANIZED ANTIBODIES WITH INCREASED STABILITY | April 2019 | March 2021 | Allow | 23 | 0 | 1 | Yes | No |
| 16398226 | SOLUBLE TCR MOLECULES AND METHODS OF USE | April 2019 | May 2022 | Abandon | 36 | 2 | 0 | No | No |
| 16345623 | NOVEL IMMUNOTHERAPEUTIC TREATMENTS FOR TUMOURS | April 2019 | December 2023 | Abandon | 56 | 4 | 1 | No | No |
| 16392418 | NOVEL ANTI-HUMAN Ig� ANTIBODS | April 2019 | May 2021 | Allow | 25 | 1 | 0 | No | No |
| 16389356 | BISPECIFIC IGG ANTIBODIES AS T CELL ENGAGERS | April 2019 | April 2024 | Allow | 60 | 7 | 0 | Yes | No |
| 16342582 | ILT3 LIGAND | April 2019 | February 2022 | Allow | 34 | 3 | 1 | Yes | No |
| 16384811 | NOVEL ANTI-HUMAN BDCA-2 ANTIBODY | April 2019 | February 2021 | Allow | 22 | 0 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JUEDES, AMY E.
With a 9.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 4.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner JUEDES, AMY E works in Art Unit 1644 and has examined 974 patent applications in our dataset. With an allowance rate of 39.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner JUEDES, AMY E's allowance rate of 39.6% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by JUEDES, AMY E receive 2.50 office actions before reaching final disposition. This places the examiner in the 69% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by JUEDES, AMY E is 40 months. This places the examiner in the 23% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +49.0% benefit to allowance rate for applications examined by JUEDES, AMY E. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 12.0% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 28.3% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 36.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 35% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 63.2% of appeals filed. This is in the 42% percentile among all examiners. Of these withdrawals, 91.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 80.5% are granted (fully or in part). This grant rate is in the 84% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 4.1% of allowed cases (in the 84% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.6% of allowed cases (in the 67% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.